Logo image of RANI

RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Fundamental Analysis

NASDAQ:RANI - US7530181004 - Common Stock

0.5101 USD
-0.03 (-5.5%)
Last: 8/29/2025, 8:00:01 PM
0.51 USD
0 (-0.02%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

0

Overall RANI gets a fundamental rating of 0 out of 10. We evaluated RANI against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RANI have multiple concerns. RANI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RANI had negative earnings in the past year.
In the past year RANI has reported a negative cash flow from operations.
RANI had negative earnings in each of the past 5 years.
RANI had a negative operating cash flow in each of the past 5 years.
RANI Yearly Net Income VS EBIT VS OCF VS FCFRANI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -175.68%, RANI is not doing good in the industry: 88.21% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -175.68%
ROE N/A
ROIC N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
RANI Yearly ROA, ROE, ROICRANI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RANI Yearly Profit, Operating, Gross MarginsRANI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
RANI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RANI has more shares outstanding
Compared to 1 year ago, RANI has a worse debt to assets ratio.
RANI Yearly Shares OutstandingRANI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RANI Yearly Total Debt VS Total AssetsRANI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -18.21, we must say that RANI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -18.21, RANI is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.21
ROIC/WACCN/A
WACC12.88%
RANI Yearly LT Debt VS Equity VS FCFRANI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 0.54 indicates that RANI may have some problems paying its short term obligations.
The Current ratio of RANI (0.54) is worse than 92.82% of its industry peers.
A Quick Ratio of 0.54 indicates that RANI may have some problems paying its short term obligations.
RANI has a worse Quick ratio (0.54) than 91.28% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
RANI Yearly Current Assets VS Current LiabilitesRANI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

RANI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.88%, which is quite impressive.
The Revenue has been growing slightly by 0.96% on average over the past years.
EPS 1Y (TTM)22.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.96% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.44%
EPS Next 2Y26.9%
EPS Next 3Y17.79%
EPS Next 5Y11.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RANI Yearly Revenue VS EstimatesRANI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 2028 2029 2030 2031 2032 100M 200M 300M 400M
RANI Yearly EPS VS EstimatesRANI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RANI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RANI Price Earnings VS Forward Price EarningsRANI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RANI Per share dataRANI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

RANI's earnings are expected to grow with 17.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.9%
EPS Next 3Y17.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RANI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (8/29/2025, 8:00:01 PM)

After market: 0.51 0 (-0.02%)

0.5101

-0.03 (-5.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)N/A N/A
Inst Owners11.97%
Inst Owner Change78.25%
Ins Owners1.76%
Ins Owner Change0%
Market Cap36.66M
Analysts82.22
Price Target8.93 (1650.64%)
Short Float %2.86%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.71%
Min EPS beat(2)-6.08%
Max EPS beat(2)9.5%
EPS beat(4)2
Avg EPS beat(4)1.15%
Min EPS beat(4)-7.31%
Max EPS beat(4)9.5%
EPS beat(8)5
Avg EPS beat(8)0.32%
EPS beat(12)9
Avg EPS beat(12)5.57%
EPS beat(16)13
Avg EPS beat(16)15.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.18%
PT rev (3m)-20.45%
EPS NQ rev (1m)18.52%
EPS NQ rev (3m)35.29%
EPS NY rev (1m)19.95%
EPS NY rev (3m)45.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.58%
Revenue NY rev (3m)-99.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.55
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.02
BVpS-0.08
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.02%
Cap/Sales 20.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -18.21
F-Score3
WACC12.88%
ROIC/WACCN/A
Cap/Depr(3y)156.71%
Cap/Depr(5y)155.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
EPS Next Y50.44%
EPS Next 2Y26.9%
EPS Next 3Y17.79%
EPS Next 5Y11.96%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.88%
EBIT Next 3Y-5.54%
EBIT Next 5Y14.98%
FCF growth 1Y40.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.54%
OCF growth 3YN/A
OCF growth 5YN/A